Evidence map›Paper›PMID 41695613›Full record

ArticleJournal of toxicology2026

Empagliflozin Alleviates Arsenic Trioxide-Induced Nephrotoxicity by Activating the SIRT1/Akt/Nrf2 Pathway.

Chunrong Pang, Wenlei Zhang, Chenli Yue, Haoxuan Li, Jinyan Li, Xinru Wang, Xinsheng Duan, Longyu Li, Zengliang Gao, Xin Hai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chunrong PangDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Wenlei ZhangDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Chenli YueDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Haoxuan LiDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Jinyan LiDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Xinru WangDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Xinsheng DuanDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Longyu LiDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Zengliang GaoDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Xin HaiDepartment of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.ORCID https://orcid.org/0000-0002-0360-8973

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arsenic trioxide (ATO), utilized in the treatment of acute promyelocytic leukemia (APL), presents significant renal toxicity that restricts its clinical usage. The potential effects of empagliflozin (EMPA) on ATO-induced nephrotoxicity remain unexplored. This study aims to investigate whether EMPA can alleviate ATO-induced nephrotoxicity in both animal and cellular models, as well as to further explore the underlying mechanisms. EMPA can improve renal function in mice and alleviate ATO-induced structural damage to the kidneys. EMPA treatment effectively inhibits ATO-induced oxidative stress and reduces apoptosis. EMPA significantly decreases the production of ROS in cultured HEK293T cells, lowers the apoptotic rate, and safeguards mitochondrial function. EMPA upregulates the SIRT1/Akt/Nrf2 pathway and addresses ATO-induced autophagy dysfunction. These findings suggest that EMPA may ameliorate ATO-induced renal toxicity by activating the SIRT1/Akt/Nrf2 signaling pathway, which is associated with the suppression of oxidative stress, reduction of apoptosis, and protection of mitochondrial functionality.

Indexed as

acute promyelocytic leukemiaarsenic trioxideautophagyempagliflozinnephrotoxicity

Identifiers

PMID41695613
PMCPMC12902901

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.